An updated assessment of the efficacy and safety of selpercatinib in patients with RET fusion-positive NSCLC treated in the phase I/II LI-BRETTO-001 trial showed an overall response rate (ORR) of 84% and 61% in treatment-naive patients and patients with prior platinum-based chemotherapy, respectively. Here, RET is linked to non-small cell lung carcinoma.